EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy

The selection of colorectal cancer patients for anti-epidermal growth factor receptor (EGFR) antibody therapy is based on the determination of their RAS mutation status—a strongly negative predictive factor—since the protein target, EGFR, is not a reliable predictor of therapeutic response. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhlyarik, Andrea, Piurko, Violetta, Papai, Zsuzsanna, Raso, Erzsebet, Lahm, Erika, Kiss, Edina, Sikter, Marta, Vachaja, Jozsef, Kenessey, Istvan, Timar, Jozsef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139947/
https://www.ncbi.nlm.nih.gov/pubmed/32155907
http://dx.doi.org/10.3390/cancers12030614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139947/
https://www.ncbi.nlm.nih.gov/pubmed/32155907
http://dx.doi.org/10.3390/cancers12030614

Ejemplares similares